Tango Therapeutics Reports Third Quarter 2026 Financial Results
Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progre
How this was made
The 30-second read
Why it matters
The data represent a material clinical milestone that could accelerate valuation and partnership interest.
Market read
First disclosure of strong efficacy data for a pancreatic cancer combo; likely catalyst for stock movement and sector sentiment.
What to watch
High cash burn and upcoming costly Phase 3 trial could strain finances if data does not translate.
Tango reports no collaboration revenue in Q3 2026 and a $68.4 million net loss, while advancing vopimetostat plus daraxonrasib toward a Phase 3 study in front-line pancreatic cancer
Clinical and regulatory progress was reported in pancreatic cancer, with 82% ORR and 88% 9-month PFS from the combination study. Financially, collaboration revenue was $0 against $53.8 million a year earlier, operating expenses rose sharply, and the Q3 2026 net loss of $68.4 million compares with net income of $15.9 million in Q3 2025.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, Q3 2026 (three months ended Sept 30)GAAP | $0 | – | – |
| Collaboration revenue, nine months 2026 (nine months ended Sept 30)GAAP | $0 | – | – |
| Research and development expenses, Q3 2026GAAP | $48.9M | – | – |
| Research and development expenses, nine months 2026GAAP | $119.7M | – | – |
| General and administrative expenses, Q3 2026GAAP | $29.2M | – | – |
| General and administrative expenses, nine months 2026GAAP | $67M | – | – |
| Total operating expenses, Q3 2026GAAP | $78.12M | – | – |
| Total operating expenses, nine months 2026GAAP | $186.7M | – | – |
| Loss from operations, Q3 2026GAAP | −$78.12M | – | – |
| Loss from operations, nine months 2026GAAP | −$186.7M | – | – |
| Other income, net, Q3 2026GAAP | $9.72M | – | – |
| Other income, net, nine months 2026GAAP | $17.42M | – | – |
| Loss before income taxes, Q3 2026GAAP | −$68.39M | – | – |
| Loss before income taxes, nine months 2026GAAP | −$169.2M | – | – |
| Net loss, Q3 2026GAAP | −$68.39M | – | – |
| Net loss, nine months 2026GAAP | −$169.2M | – | – |
| Net loss per common share, basic and diluted, Q3 2026GAAP | $(0.39) | – | – |
| Net loss per common share, basic and diluted, nine months 2026GAAP | $(1.08) | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
What drove it
- Collaboration revenue was $0 in 2026 because all remaining deferred revenue from the upfront and research option-extension payments under the Gilead collaboration was recognized during the year ended December 31, 2025, as a result of the truncation of the collaboration agreement, which concluded all research activities in August 2025.
- The Company said the increase in R&D expenses was primarily due to increased spend on the advancement of the vopimetostat and TNG456 clinical programs, partially offset by decreased spend due to portfolio prioritization efforts.
- The Company said the increase in G&A expenses was primarily due to increased personnel-related costs, including share-based compensation expense, which included increases derived from the modification of previously issued equity awards for former executive officers.
- Other income, net rose to $9,722 thousand in Q3 2026 from $1,802 thousand in Q3 2025. The filing does not explain the change.
Concerns
- No collaboration revenue was reported in Q3 2026 or the nine months 2026, compared with $53.8 million in Q3 2025 and $62.4 million in the nine months 2025.
- Operating expenses rose to $78,116 thousand in Q3 2026 from $39,739 thousand in Q3 2025, which turned the operating result from income to a loss.
- The filing does not state how long the $977.5 million in cash, cash equivalents and marketable securities will fund operations, and it names the operating plan as the basis.
- The G&A increase includes share-based compensation tied to the modification of equity awards for former executive officers.
What to watch
- Initiation of the planned global, randomized Phase 3 study of vopimetostat 200 mg plus daraxonrasib 100 mg once-daily versus standard-of-care chemotherapy in front-line MTAP-deleted pancreatic cancer, planned for the first half of 2027.
- Initiation of the Phase 1/2 study of vopimetostat plus a panRAS inhibitor in MTAP-wild type pancreatic cancer, of approximately 25 patients, planned for the first half of 2027.
- Disclosure of vopimetostat lung cancer monotherapy data and TNG456 data in lung cancer, glioblastoma and other cancers, both planned for January 2027.
- Engagement with regulators on possible accelerated approval of the combination in second line pancreatic cancer, which the Company said it intends to discuss.
- Enrollment progress in the Erasca-partnered Phase 1/2 study of vopimetostat with ERAS-0015 in MTAP-deleted PDAC and MTAP-deleted/RAS-mutant NSCLC, which the Company said has initiated enrollment in November 2026.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $977.5 million as of September 30, 2026, which the Company expects to fund its current operating plan.
- Cash and cash equivalents were $86,835 thousand at September 30, 2026, compared with $112,279 thousand at December 31, 2025.
- Marketable securities were $890,668 thousand at September 30, 2026, compared with $230,859 thousand at December 31, 2025.
- Total assets were $1,033,460 thousand at September 30, 2026, compared with $398,690 thousand at December 31, 2025.
- Total liabilities were $53,287 thousand at September 30, 2026, compared with $52,511 thousand at December 31, 2025.
- Total stockholders' equity was $980,173 thousand at September 30, 2026, compared with $346,179 thousand at December 31, 2025.
- No operating cash flow, free cash flow or cash flow statement is included in the filing.
Analysis
Tango reported no collaboration revenue for Q3 2026 or the nine months 2026. The Company attributes this to the recognition of all remaining Gilead deferred revenue during 2025, following the truncation of the collaboration agreement, which concluded research activities in August 2025. Against the prior-year periods, collaboration revenue of $53.8 million in Q3 2025 and $62.4 million in the nine months 2025 is therefore absent from the 2026 results, so the year-over-year comparison is driven by the revenue line alone.
Operating expenses increased in both periods. R&D expenses were $48.9 million in Q3 2026 against $30.8 million in Q3 2025, and $119.7 million for the nine months 2026 against $100.1 million. The Company attributes the R&D increase to spend on the vopimetostat and TNG456 clinical programs, partly offset by portfolio prioritization. G&A expenses were $29.2 million in Q3 2026 against $8.9 million, and $67.0 million for the nine months against $31.7 million. The Company attributes the G&A increase mainly to personnel-related costs, including share-based compensation tied to the modification of equity awards for former executive officers. Total operating expenses were $78,116 thousand in Q3 2026 against $39,739 thousand a year earlier, and the loss from operations was $(78,116) thousand against income of $14,072 thousand.
Below the operating line, other income, net was $9,722 thousand in Q3 2026 against $1,802 thousand in Q3 2025. The net loss was $(68,394) thousand, or $(0.39) per share, in Q3 2026, compared with net income of $15,884 thousand, or $0.14 per share basic and $0.13 per share diluted, in Q3 2025. For the nine months, the net loss was $(169,249) thousand, or $(1.08) per share, against a net loss of $(62,845) thousand, or $(0.57) per share, a year earlier. These figures are GAAP. The filing reports no non-GAAP measures.
The balance sheet shows $977.5 million in cash, cash equivalents and marketable securities at September 30, 2026, up from a combined position that the filing does not state for December 31, 2025. Marketable securities were $890,668 thousand against $230,859 thousand at December 31, 2025, and total stockholders' equity was $980,173 thousand against $346,179 thousand. The Company states that this cash is expected to fund its current operating plan, but it gives no runway duration and no cash flow statement. No guidance is provided.
The operating story is clinical and regulatory. The Company reported 82% ORR and 88% nine-month PFS rate for vopimetostat plus daraxonrasib at ESMO in October 2026, in second and third line pancreatic ductal adenocarcinoma, and it plans a Phase 3 study in front-line MTAP-deleted pancreatic cancer in the first half of 2027, after discussions with the FDA. The filing does not disclose the number of efficacy-evaluable patients beyond the August 20, 2026 data cutoff stated in the release. The next readouts are lung cancer and TNG456 data in January 2027.
Management, verbatim
In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer.
Malte Peters, MD, President and Chief Executive Officer
Based on those data, we have engaged with the FDA on our plans for a registrational study in the front-line setting and plan to initiate that study in the first half of next year.
Malte Peters, MD, President and Chief Executive Officer
Not in the filing
stated, not guessed- No financial guidance for revenue, gross margin, operating expenses or tax rate is provided, so guidance and vs_prior_guidance are null or empty.
- No segment reporting is provided; collaboration revenue is the only revenue line and is shown under key_metrics.
- The filing does not state year-over-year or quarter-over-quarter percentage changes for any line.
- No prior-quarter (Q2 2026) figures are printed, so prior_quarter and qoq_change are null for all rows.
- Diluted EPS for Q3 2025 ($0.13) is printed in the text, but basic EPS ($0.14) is the value placed in prior_year for the Q3 comparison.
- No cash flow statement is provided; operating cash flow and free cash flow are not reported.
- No combined cash, cash equivalents and marketable securities figure is printed for December 31, 2025.
- The filing does not state a cash runway duration beyond the statement that cash is expected to fund the current operating plan.
- No share repurchase or dividend activity is reported.
- The filing does not state a share-price reaction or analyst consensus, and none is included here.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Tango Therapeutics filed an 8‑K announcing Q3 financials and presenting new Phase 1/2 efficacy data from an ESMO presentation.
Ticker impact
SEC 8‑K reports Q3 2026 results and first public Phase 1/2 data showing 82% ORR and 88% 9‑month PFS for vopimetostat + daraxonrasib in pancreatic cancer.
likely upward pressure as investors price in promising efficacy and upcoming Phase 3 initiation.
First disclosure of high‑response rates in a late‑stage oncology combo; biotech stocks typically rally on such data.
Market effects
Boosts sentiment for PRMT5‑targeted oncology pipelines and may lift peer biotech stocks.
Positive for US biotech sector and Nasdaq biotech indices.
Highlights potential new therapy for pancreatic cancer, relevant to global oncology market.
Counterpoint
Skeptics may question durability of response rates and the path to regulatory approval.
Key entities
- companyTango Therapeutics, Inc.
Clinical‑stage biotech developing PRMT5 inhibitors.
- partnerRevolution Medicines
Provider of the RAS(ON) inhibitor daraxonrasib used in the combo.
